Note 10 - Collaboration and License Agreements (Tables)

9 Months Ended

Sep. 30, 2013

Abbott [Member]

Note 10 - Collaboration and License Agreements (Tables) [Line Items]

Deferred Revenue, by Arrangement, Disclosure [Table Text Block]

(In thousands)	Amount Deferred at December 31, 2012		Cash Received for the Nine Months Ended  September 30, 2013		Revenue Recognized for the Nine Months Ended September 30, 2013		Change in Accounts Receivable for the Nine Months Ended September 30, 2013		Foreign Currency Effects for the Nine Months Ended September 30, 2013			Amount Deferred at September 30, 2013
Collaboration revenue:
Up-front payment associated with the Company's   obligation to participate in joint committees	$	725	$	-	$	18	$	-	$	(101	)	$	606
Product sales revenue:	$	-	$	9,437	$	10,680	$	1,124	$	119		$	-

Takeda [Member]

Note 10 - Collaboration and License Agreements (Tables) [Line Items]

Deferred Revenue, by Arrangement, Disclosure [Table Text Block]

(In thousands)	Amount Deferred at December 31, 2012		Cash Received for the Nine Months Ended  September 30, 2013		Revenue Recognized for the Nine Months Ended September 30, 2013			Change in Accounts Receivable for the Nine Months Ended September 30, 2013*			Amount Deferred at September 30, 2013
Collaboration revenue:
Up-front payment associated with the Company's    obligation to participate in joint committees	$	1,176	$	-	$	110	$	-		$	1,066
Research and development revenue:
Up-front payment - remainder	$	-	$	-	$	-	$	-		$	-
Development milestones		-		10,000		10,000		-			-
Reimbursement of research and development expenses		249		8,010		6,288		(1,657	)		314
Total	$	249	$	18,010	$	16,288	$	(1,657	)	$	314
Product royalty revenue	$	-	$	37,852	$	37,271	$	(581	)		-
Co-promotion revenue	$	-	$	839	$	61	$	(778	)		-